Biologic therapies in systemic lupus erythematosus

2015 ◽  
Vol 18 (2) ◽  
pp. 146-153 ◽  
Author(s):  
Christine B. Bernal ◽  
Leonid D. Zamora ◽  
Sandra V. Navarra
Author(s):  
Maria Mouyis ◽  
David Isenberg

This chapter looks at the various biologic or target therapies that have been trialled and tested in the last two decades. The treatment of systemic lupus erythematosus (SLE) has progressed over the last few years due to an increased understanding of its pathogenesis; beginning with rituximab, one of the first biologics to be used, the chapter covers therapies up to the present day. Each subsection highlights the relevant mechanism of action which has led to new treatment options: anti-CD20 and 22, anti-B cell activating factors, anti-interferon alpha and anti-T cell activation. A summarized table is available providing a concise summary of the latest biologic therapies in treating SLE. The role of biologic therapies as monotherapy is still being defined, and with time there will be further change in the treatments available and the approach to the treatment of SLE using biologic therapies.


BioDrugs ◽  
2013 ◽  
Vol 28 (2) ◽  
pp. 211-228 ◽  
Author(s):  
Helena Hiemisch Lobo Borba ◽  
Astrid Wiens ◽  
Thais Teles de Souza ◽  
Cassyano Januário Correr ◽  
Roberto Pontarolo

2016 ◽  
Vol 18 (7) ◽  
Author(s):  
Helena Hiemisch Lobo Borba ◽  
Andreas Funke ◽  
Astrid Wiens ◽  
Shirley Ramos da Rosa Utiyama ◽  
Cássio Marques Perlin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document